Lowering Mutant Huntingtin Levels and Toxicity: Autophagy-Endolysosome Pathways in Huntington's Disease

被引：31
|
作者：
Valionyte, Evelina [1 ,2 ]
Yang, Yi [1 ,2 ]
Roberts, Sheridan L. [1 ,2 ]
Kelly, Jack [1 ,2 ]
Lu, Boxun [3 ]
Luo, Shouqing [1 ,2 ]
机构：
[1] Univ Plymouth, Peninsula Sch Med, Inst Translat & Stratified Med, Res Way, Plymouth PL6 8BU, Devon, England
[2] Univ Plymouth, Peninsula Sch Dent, Inst Translat & Stratified Med, Res Way, Plymouth PL6 8BU, Devon, England
[3] Fudan Univ, Collaborat Innovat Ctr Brain Sci, Sch Life Sci, State Key Lab Med Neurobiol, Shanghai 200438, Peoples R China
来源：
JOURNAL OF MOLECULAR BIOLOGY | 2020年 / 432卷 / 08期
基金：
中国国家自然科学基金; 英国医学研究理事会;
关键词：
Autophagy; Selective autophagy; Huntington's disease; Huntingtin; Neu rodegeneration; INCLUSION-BODY FORMATION; SELECTIVE AUTOPHAGY; MOUSE MODEL; POLYGLUTAMINE EXPANSIONS; MOLECULAR-MECHANISMS; TRINUCLEOTIDE REPEAT; ACTIVATES AUTOPHAGY; RECEPTOR OPTINEURIN; MEDIATED AUTOPHAGY; NUCLEAR INCLUSIONS;
D O I：
10.1016/j.jmb.2019.11.012
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Huntington's disease (HD) is a monogenetic neurodegenerative disease, which serves as a model of neurodegeneration with protein aggregation. Autophagy has been suggested to possess a great value to tackle protein aggregation toxicity and neurodegenerative diseases. Current studies suggest that autophagyendolysosomal pathways are critical for HD pathology. Here we review recent advancement in the studies of autophagy and selective autophagy relating HD. Restoration of autophagy flux and enhancement of selective removal of mutant huntingtin/disease-causing protein would be effective approaches towards tackling HD as well as other similar neurodegenerative disorders. (C) 2019 Elsevier Ltd. All rights reserved.
引用
收藏
页码：2673 / 2691
页数：19
相关论文
共 50 条
  • [21] Longitudinal Evaluation Of The First Mutant Huntingtin PET Radioligand As A Marker For mHTT Lowering Therapies For Huntington's Disease
    Bertoglio, D.
    Verhaeghe, J.
    De Lombaerde, S.
    Zajicek, F.
    Vasilkovska, T.
    Miranda, A.
    Gaertner, A.
    Huscher, B.
    Kakoulidou, A.
    Cardaun, I.
    Cornelius, A.
    Schwagarus, T.
    Van der Linden, A.
    Stroobants, S.
    Wang, Y.
    Skinbjerg, M.
    Dominguez, C.
    Khetarpal, V.
    Liu, L.
    Munoz-Sanjuan, I.
    Bard, J.
    Staelens, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S129 - S129
  • [22] Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease
    Ehrnhoefer, Dagmar E.
    Martin, Dale D. O.
    Schmidt, Mandi E.
    Qiu, Xiaofan
    Ladha, Safia
    Caron, Nicholas S.
    Skotte, Niels H.
    Nguyen, Yen T. N.
    Vaid, Kuljeet
    Southwell, Amber L.
    Engemann, Sabine
    Franciosi, Sonia
    Hayden, Michael R.
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2018, 6 : 16
  • [23] Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model
    Wang, WF
    Duan, WZ
    Igarashi, S
    Morita, H
    Nakamura, M
    Ross, CA
    NEUROBIOLOGY OF DISEASE, 2005, 20 (02) : 500 - 508
  • [24] Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease
    Dagmar E. Ehrnhoefer
    Dale D. O. Martin
    Mandi E. Schmidt
    Xiaofan Qiu
    Safia Ladha
    Nicholas S. Caron
    Niels H. Skotte
    Yen T. N. Nguyen
    Kuljeet Vaid
    Amber L. Southwell
    Sabine Engemann
    Sonia Franciosi
    Michael R. Hayden
    Acta Neuropathologica Communications, 6
  • [25] Esculetin Provides Neuroprotection against Mutant Huntingtin-Induced Toxicity in Huntington's Disease Models
    Pruccoli, Letizia
    Breda, Carlo
    Teti, Gabriella
    Falconi, Mirella
    Giorgini, Flaviano
    Tarozzi, Andrea
    PHARMACEUTICALS, 2021, 14 (10)
  • [26] Dose-Dependent Lowering of Mutant Huntingtin Using Antisense Oligonucleotides in Huntington Disease Patients
    van Roon-Mom, Willeke M. C.
    Roos, Raymund A. C.
    de Bot, Susanne T.
    NUCLEIC ACID THERAPEUTICS, 2018, 28 (02) : 59 - 62
  • [27] Parallel evaluation of mutant huntingtin and neurofilament light in Huntington's disease
    Byrne, L.
    Rodrigues, F.
    Johnson, E.
    De Vita, E.
    Czech, C.
    Schobel, S.
    Scahill, R.
    Heslegrave, A.
    Zetterberg, H.
    Wild, W.
    MOVEMENT DISORDERS, 2018, 33 : S370 - S374
  • [28] Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease
    Wellington, CL
    Ellerby, LM
    Gutekunst, CA
    Rogers, D
    Warby, S
    Graham, RK
    Loubser, O
    van Raamsdonk, J
    Singaraja, R
    Yang, YZ
    Gafni, J
    Bredesen, D
    Hersch, SM
    Leavitt, BR
    Roy, S
    Nicholson, DW
    Hayden, MR
    JOURNAL OF NEUROSCIENCE, 2002, 22 (18): : 7862 - 7872
  • [29] Huntington’s disease cerebrospinal fluid seeds aggregation of mutant huntingtin
    Z Tan
    W Dai
    T G M van Erp
    J Overman
    A Demuro
    M A Digman
    A Hatami
    R Albay
    E M Sontag
    K T Potkin
    S Ling
    F Macciardi
    W E Bunney
    J D Long
    J S Paulsen
    J M Ringman
    I Parker
    C Glabe
    L M Thompson
    W Chiu
    S G Potkin
    Molecular Psychiatry, 2015, 20 : 1286 - 1293
  • [30] Development of a ligand for in vivo imaging of mutant huntingtin in Huntington's disease
    Bertoglio, Daniele
    Bard, Jonathan
    Hessmann, Manuela
    Liu, Longbin
    Gaertner, Annette
    De Lombaerde, Stef
    Huscher, Britta
    Zajicek, Franziska
    Miranda, Alan
    Peters, Finn
    Herrmann, Frank
    Schaertl, Sabine
    Vasilkovska, Tamara
    Brown, Christopher J.
    Johnson, Peter D.
    Prime, Michael E.
    Mills, Matthew R.
    Van der Linden, Annemie
    Mrzljak, Ladislav
    Khetarpal, Vinod
    Wang, Yuchuan
    Marchionini, Deanna M.
    Skinbjerg, Mette
    Verhaeghe, Jeroen
    Dominguez, Celia
    Staelens, Steven
    Munoz-Sanjuan, Ignacio
    SCIENCE TRANSLATIONAL MEDICINE, 2022, 14 (630)
12345